New technology also can be used to turn off peanut and other food allergies
In an entirely new approach to treating asthma and allergies, a biodegradable nanoparticle acts like a Trojan horse, hiding an allergen in a friendly shell, to convince the immune system not to attack it, according to new Northwestern Medicine research. As a result, the allergic reaction in the airways is shut down long- term and an asthma attack prevented.
The technology can be applied to food allergies as well. The nanoparticle is currently being tested in a mouse model of peanut allergy, similar to food allergy in humans.
“The findings represent a novel, safe and effective long-term way to treat and potentially ‘cure’ patients with life-threatening respiratory and food allergies,” said senior author Stephen Miller, the Judy Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine. “This may eliminate the need for life-long use of medications to treat lung allergy.”
It’s the first time this method for creating tolerance in the immune system has been used in allergic diseases. The approach has been used in autoimmune diseases including multiple sclerosis and celiac disease in previous preclinical Northwestern research.
The asthma allergy study was in mice, but the technology is progressing to clinical trials in autoimmune disease. The nanoparticle technology is being developed commercially by Cour Pharmaceuticals Development Co., which is working with Miller to bring this new approach to patients. A clinical trial using the nanoparticles to treat celiac disease is in development.
The new study on nanoparticles treating asthma was published April 18 in the Proceedings of the National Academy of Sciences.
“It’s a universal treatment,” Miller said. “Depending on what allergy you want to eliminate, you can load up the nanoparticle with ragweed pollen or a peanut protein.”
The nanoparticles are composed of an FDA-approved biopolymer called PLGA that includes lactic acid and glycolic acid.
Also a senior author is Lonnie Shea, adjunct professor of chemical and biological engineering at Northwestern’s McCormick School of Engineering and of obstetrics and gynecology at Feinberg, and chair of biomedical engineering at the University of Michigan.
When the allergen-loaded nanoparticle is injected into the bloodstream of mice, the immune system isn’t concerned with it because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.
The allergen, in this case egg protein, was administered into the lungs of mice who have been pretreated to be allergic to the protein and already had antibodies in their blood against it. So when they were re-exposed to it, they responded with an allergic response like asthma. After being treated with the nanoparticle, they no longer had an allergic response to the allergen.
The approach also has a second benefit. It creates a more normal, balanced immune system by increasing the number of regulatory T cells, immune cells important for recognizing the airway allergens as normal. This method turns off the dangerous Th2 T cell that causes the allergy and expands the good, calming regulatory T cells.
The Latest on: Nanoparticles asthma allergies
via Google News
The Latest on: Nanoparticles asthma allergies
- Neosinus enters into Strategic Partnership with DailyBreath to Collaborate on Improving Allergy and Asthma Managementon July 1, 2021 at 5:07 am
Neosinus Health, an emerging and award-winning drug development platform company, which has commercialized a fully integrated platform for optimizing drug delivery and health outcomes, has partnered ...
- Wayne State awarded NSF grant to investigate how viruses navigate through the mucus barrieron June 28, 2021 at 10:25 pm
including asthma, bronchitis, cystic fibrosis, etc. The overarching goal of this project is to help fight diseases and develop engineered nanoparticles for more efficient drug or gene delivery.
- Allergist, Vaccine Researchers Nothing to Sneeze At, UCD Judges Sayon June 18, 2021 at 5:00 pm
A startup that’s trying to promote a better way to treat allergy patients beat out a ... Nanoly’s goal is to develop a nanoparticle polymer and buffer agent that can be blended safely with ...
- Genetically engineered cell membrane–coated nanoparticles for targeted delivery of dexamethasone to inflamed lungson June 17, 2021 at 7:15 am
Here, the specific affinity between very late antigen–4 (VLA-4) and VCAM-1 is exploited to produce a biomimetic nanoparticle formulation capable of targeting inflammation. The plasma membrane from ...
- The hobby with hidden health riskson June 10, 2021 at 10:58 pm
It's a proven culprit of asthma, allergic rhinitis ... very small particles – nanoparticles actually, and they're the ones that are the biggest concern at the moment," says Yates.
- The Science Gives Moderna A Booston June 8, 2021 at 10:15 am
The thing that allows mRNA to be ferried across the cell membrane walls is something called liquid nanoparticles or ... inflammatory bowel disease, Asthma & Allergy, Cardiovascular disease ...
- Subcutaneous Versus Sublingual Immunotherapy for Allergic Rhinitis and/or Asthmaon June 5, 2021 at 5:00 pm
 Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) improve symptoms in allergic rhinitis and/or asthma. SCIT and SLIT decrease medication use in allergic rhinitis and/or ...
- European Workers Face Increasing Health Risks From Hazardous Substanceson June 3, 2021 at 4:59 pm
The report, Expert Forecast on Emerging Chemical Risks, identifies the main groups of substances that could pose new and increasing risks to workers, contributing to diseases ranging from allergies, ...
- NIH launches clinical trial of universal influenza vaccine candidateon June 1, 2021 at 11:26 pm
A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza ... from NIH's National Institute of Allergy and Infectious Diseases (NIAID ...
- Asthma & COPD Market to Score Past US$ 42,608.1 Million Valuation by 2027, Says Coherent Market Insightson June 1, 2021 at 5:02 am
For instance, in July 2020, The Asthma and Allergy Foundation of America has published a concise guide, “COVID-19 and Asthma Toolkit for Schools,” to assist educators and families with ...
via Bing News